Strategic merger with Rafael Holdings to combine two companies and advance Trappsol® Cyclo™ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to European Medicines Agency (EMA) targeted for H2 2025 Qualification for Priority Review Voucher expected upon NDA submission Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through sci

NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. "During fiscal 2024, we made significant progress on our strategy to advance our existing portfolio and to invest in, develop and commercialize clinical stage assets in areas of high unmet medical need. Specifically, we are extremely pleased to have entered into a merger agreement with Cyclo Therapeutics (NASDAQ:CYTH)," said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are encouraged that Cyclo Therapeutics has fully enrolled its pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the tre

TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company's financial operations. "We are delighted to welcome Shawn as our new Chief Financial Officer and look forward to his leadership and guidance as we invest in long-term growth and value creation while maintaining high standards in resource allocation and execution," said Frank D. Lee, chief executive officer of Pacira BioSciences. "Shawn brings a strong set of experienc

Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Trappsol® Cyclo™ demonstrated to be well tolerated in ongoing substudy with a safety profile consistent with that of completed phases Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

Quarter marked by achievement of landmark milestone with completion of enrollment in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2024 and provided a business update. "The second quarter represents a

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a notice from the European Patent Office of a decision to grant European patent application No. 19805439.7 titled, "Methods for Treating Alzheimer's Disease" under European patent number 3873604B. The notice states that mention of the decision will be published on August 21, 2024 in European Patent Bulletin 24/34 and will take effect on that date. N. Scott Fine, CEO of Cyclo Therapeutics, commented, "This

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that two abstracts have been accepted for poster presentation at the SSIEM Annual Symposium 2024 being held September 3-6, 2024 in Porto, Portugal. "We truly value the opportunity and are honored to present our data at this preeminent scientific congress to further strengthen our voice within the NPC community. Our TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprin

NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. "During fiscal 2024, we have continued to develop our existing portfolio while actively evaluating opportunities for strategic investment," said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are particularly pleased that Cyclo Therapeutics (NASDAQ:CYTH) announced the completion of enrollment in its pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease. We are also encouraged by the execution at Day

https://register.epo.org/application?number=EP19805439

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and maintains $3 price target.

TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1)Topline data from the 48-week interim analysis of 104 enrolled patients is anticipated for H1 2025

Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent. The company reported quarterly sales of $202.450 thousand which missed the analyst consensus estimate of $376.667 thousand by 46.25 percent. This is a 32.83 percent increase over sales of $152.411 thousand the same period last year.

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces Price Target of $3.

Ascendiant Capital analyst Lucas Ward initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces Price Target of $2.6.

Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) shares moved upwards by 8.4% to $0.65. The market value of their outstanding shares is at $23.2 million. Mustang Bio (NASDAQ:MBIO) shares rose 7.78% to $0.4. The market value of their outstanding shares is at $4.1 million. BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 7.46% to $1.44. The market value of their outstanding shares is at $20.1 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by 7.14% to $1.65. The company's market cap stands at $3.2 million. China SXT Pharmac

Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (NASDAQ:AIH) shares rose 43.48% to $0.49. The market value of their outstanding shares is at $23.1 million. Sight Sciences (NASDAQ:SGHT) shares rose 20.77% to $6.57. The market value of their outstanding shares is at $325.5 million. Inspire Veterinary (NASDAQ:IVP) stock increased by 16.59% to $0.05. The market value of their outstanding shares is at $1.7 million. GlycoMimetics (NASDAQ:GLYC) stock rose 6.41% to $3.15. The market value of their outstanding shares is at $203.0 million. As per t

https://register.epo.org/application?number=EP19805439

Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

– Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha

Continued progress in lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter of 2021, and provided a business update. "We have executed on multiple fronts over the course of the third quarter. Our pivotal Phase 3 study evaluating Trappsol® Cyclo™ as a potential treatment for Niemann-Pick Disease, TransportNPC™,

– Dr. Lemere is a renowned translational researcher focused on understanding, preventing, and treating Alzheimer's disease – Company continues to advance evaluation of Trappsol® Cyclo™ toward Phase 2 study in Alzheimer's disease with investigational new drug application (IND) filing on track before year end Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Cynthia A. Lemere, PhD as Senior Advisor for its Alzheimer's disease program. Dr. Lemere is a distinguishe

- Dr. Kjems is a leading global physician scientist with a proven pharma track record of drug development across multiple therapeutic areas, including chronic indications, oncology and rare diseases - - Gerald F. Cox, MD, PhD will continue offering clinical development leadership, worldwide regulatory expertise and access to expansive network as a member of the Company's Scientific Advisory Board - Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjem

Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communities Formerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, announced today it has appointed Lori McKenna Gorski as Global Head of Patient Advocacy. "The unmet needs of patients and their families remain at the forefront for Cyclo Therapeutics as we drive the develo

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced the appointment of Russ Belden as Acting Chief Commercial Officer. Mr. Belden is a commercialization leader with over 33 years of senior leadership experience in the biotechnology industry, specializing in strategic marketing, sales management, sales training, and product development. Through his firm, Mr. Belden has worked with over 60 pre-clinical, early-launch phase therapeutics and

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced the appointment of Gerald F. Cox, MD, PhD as Acting Chief Medical Officer. Dr. Cox is an internationally renowned biotechnology executive with over 20 years of experience in drug development for rare diseases. Over the course of his career, he has made major contributions to more than 15 Investigational New Drug applications (INDs) and 6 orphan drug marketing authorizations for serious and life-threate